NCT06845241View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2028

Conditions

Relapsed or Refractory Non-Hodgkin Lymphoma

Interventions

DRUG

ICP-490

Specified dose on specified days

Trial Locations (6)

300000

Tianjin Medical University Cancer Institute & Hospital, Tianjin

330000

The First Affiliated Hospital of Nanchang University, Nanchang

350014

Fujian Cancer Hospital, Fuzhou

450000

Henan Cancer Hosptital, Zhengzhou

510000

Sun Yat-sen University Cancer Center, Guangzhou

650000

The Second Affiliated Hospital of Kunming Medical University, Kunming

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT06845241 - Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter